Several low-priced pharmaceutical preparations, which, however, remain valuable and irreplaceable for the patients who receive them, are being withdrawn from the drug market, reports the Panhellenic Pharmaceutical Association (PFS).

“The phenomenon is observed more and more often, as for example recently happened with the preparation prezolon tabl 5mg which has a retail price of 1 euro and its circulation is stopped at the request of the company that produces it, because it is no longer of substantial commercial and financial interest to the company ».

The PFS expresses the certainty that those withdrawn, “will either be replaced in the prescription by more expensive preparations and treatments, or the state pharmacy IFET will be forced to import the preparations of the same active substance from abroad at a multiple price, burdening the budget of the insurance funds but also the pocket of the patients, as the participation they pay increases due to the price increase”.

The phenomenon of withdrawal from the market of drugs whose price fluctuates at very low levels will be prevented, the PFS estimates, by taking immediate measures to support the retail price of these drugs and formulating an appropriate policy in the field of medicine, in order to protect the their circulation for reasons of public health and to continue their unhindered provision to patients who need them.